Healthcare

Business

Stifel Boosts Nurix Therapeutics Price Target to $35, Citing 2026 as Pivotal Year for Key Drug Candidate

Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.

Feb 2, 2026

Business

Jefferies Downgrades Amicus to 'Buy' Amid BioMarin Acquisition, Sees Limited Upside

Jefferies has downgraded Amicus Therapeutics to 'Buy' from 'Hold' and trimmed its price target to $14.50, aligning it with BioMarin's pending $4.8 billion acquisition offer. The move reflects analyst skepticism about competing bids emerging for the rare disease biotech firm.

Feb 2, 2026

Business

Wisconsin Labor Market Shows Resilience Despite January Layoffs Affecting 366 Workers

Seven Wisconsin employers filed WARN notices in January, yet the state's unemployment rate held steady at a low 3.1%. Economists point to a cooling but stable labor market, with significant workforce changes driven by retirements and sectoral shifts.

Feb 2, 2026

Kansas Overhauls Education Savings Program: Lower Fees, More Choices Arrive in March

TOPEKA — Kansas's popular Learning Quest 529 savings plans are set for a significant upgrade next month, promising families new investment options, enhanced planning tools, and reduced management fees under a new administrator, State Treasurer Steven Johnson announced.

Feb 2, 2026

Business

Palantir's AI Software Growth Exceeds 25% Annually, Phillip Securities Sees Major Upside with $208 Target

Phillip Securities initiates coverage of Palantir Technologies with a Buy rating, citing its AI software segment's robust growth and significant market expansion potential. A new partnership with Innodata aims to enhance Palantir's rodeo analysis platforms through advanced data services.

Feb 2, 2026

Business

IBM Bolsters Enterprise AI Strategy with New Platform, Key Partnership, and PepsiCo CEO Joining Board

IBM intensifies its focus on the enterprise AI market with the launch of its governed deployment platform, a strategic collaboration with e& for regulated sectors, and the appointment of PepsiCo's Ramon Laguarta to its board of directors.

Feb 2, 2026

Business

Edwards Lifesciences: Strong Fundamentals Mask Growth Concerns as Stock Slips

Despite a recent 4.7% stock decline, Edwards Lifesciences (NYSE: EW) boasts a robust 13% Return on Equity, outperforming its industry. Yet, its modest 4.6% five-year growth rate raises questions about future potential and market valuation.

Feb 2, 2026

World

Former Peruvian Foreign Minister Dies in Brazilian Prison Hospital While Awaiting Extradition

Augusto Blacker Miller, a controversial figure from Peru's Fujimori era, has died in a Rio de Janeiro prison hospital. The 80-year-old, arrested in Brazil last December on an Interpol warrant, succumbed to cardiorespiratory arrest, reigniting debates about justice, aging detainees, and cross-border legal accountability.

Feb 2, 2026

Business

Social Security's 2026 COLA: A Raise That Doesn't Keep Up

Millions of seniors received a 2.8% Cost-of-Living Adjustment this January, but soaring Medicare premiums and a flawed inflation formula mean their real purchasing power continues to erode, highlighting a systemic crisis for retirees.

Feb 2, 2026

As AI Penetrates Patient Care, a Patchwork of State Rules Replaces Federal Guardrails

With pharmaceutical companies increasingly deploying AI in direct-to-consumer platforms, the regulatory landscape remains fragmented. In the absence of comprehensive federal action, states are stepping in with disparate laws to address privacy and safety concerns, creating a complex compliance challenge for the industry.

Feb 2, 2026

US

Congress Returns to Washington in Race Against Clock to Avert Government Shutdown

Lawmakers reconvene Monday as House GOP leadership pushes for rapid passage of a stopgap funding bill to prevent a prolonged partial government shutdown, with tensions high over border security provisions.

Feb 2, 2026

The Silent Inheritance: How Boomers' Reluctance to Discuss Wealth Transfer Risks Family Strife and Financial Chaos

A pervasive culture of silence around estate planning is setting the stage for confusion and conflict as trillions in assets prepare to change hands. Experts warn that avoiding 'the talk' is a disservice to both generations.

Feb 2, 2026

Business

Sanofi's Pipeline Gains Momentum with Key Phase 3 Successes in Rare Disease and Immunology

Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.

Feb 2, 2026

Business

Income Shift: Three Vanguard Dividend ETFs Gaining Favor as Retirement Portfolios Rotate

As market leadership broadens beyond tech, income-focused investors are turning to high-yield dividend ETFs. Vanguard's suite offers diversified, cost-effective options for building retirement income streams in a changing landscape.

Feb 2, 2026

Business

The Silent Thief: Why Inflation Poses a Unique Threat to Retirees and How to Fight Back

For those on a fixed income, inflation isn't just an economic indicator—it's a direct assault on financial security. Experts warn that failing to plan for rising costs can halve a retiree's purchasing power over decades. Here’s a strategic guide to building a resilient portfolio.

Feb 2, 2026

World

Rafah Crossing Reopens: A Lifeline for Gaza's Civilians Amid Ongoing Conflict

The Rafah border crossing, Gaza's sole gateway to Egypt, has partially reopened for pedestrian traffic after a prolonged Israeli closure, offering a fragile hope for medical evacuations and family reunifications.

Feb 2, 2026

Business

Medicare's Obesity Drug Coverage Set to Fuel Lilly's Weight-Loss Pill Launch, CEO Says

Eli Lilly's CEO sees Medicare's new policy covering obesity treatments as a pivotal moment, poised to unlock access for millions of beneficiaries to its incoming oral drug, orforglipron, and intensify the market battle with Novo Nordisk.

Feb 2, 2026

Navigating Medicare's Maze: Three Costly Misconceptions Retirees Must Unlearn

Millions rely on Medicare, yet common misunderstandings about its coverage rules and costs can lead to significant financial shocks in retirement. We clarify three critical areas where assumptions often prove wrong.

Feb 2, 2026

Business

InflaRx's Cash Runway Narrows: Can the Biotech Steer Through Financial Headwinds?

With a cash reserve that could last just over a year at its current burn rate, InflaRx faces a critical period to prove its clinical pipeline's value. While management has reined in spending, the company's financial strategy is now under the microscope.

Feb 2, 2026

Business

Beyond the Benchmark: Two S&P 500 Stocks with Momentum and One Facing Headwinds

The S&P 500 is home to market leaders, but not all its constituents are created equal. We examine one company navigating challenges and two others positioned for potential growth, providing context on their valuations and market positions.

Feb 2, 2026